[저자] Joseph F. Standing, Laura Buggiotti, Jose Afonso Guerra-Assuncao, Maximillian Woodall, Samuel Ellis, Akosua A. Agyeman, Charles Miller, Mercy Okechukwu, Emily Kirkpatrick, Amy I. Jacobs, Charlotte A. Williams, Sunando Roy, Luz M. Martin-Bernal, Rachel Williams, Claire M. Smith, Theo Sanderson, Fiona B. Ashford, Beena Emmanuel, Zaheer M. Afzal, Adrian Shields, Alex G. Richter, Jienchi Dorward, Oghenekome Gbinigie, Oliver Van Hecke, Mark Lown, Nick Francis, Bhautesh Jani, Duncan B. Richards, Najib M. Rahman, Ly-Mee Yu, Nicholas P. B. Thomas, Nigel D. Hart, Philip Evans, Monique Andersson, Gail Hayward, Kerenza Hood, Jonathan S. Nguyen-Van-Tam, Paul Little, F. D. Richard Hobbs, Saye Khoo, Christopher Butler, David M. Lowe, Judith Breuer, PANORAMIC Virology GroupAllenJulie22BayzidNadua3BrownJulianne2BurnsDoug1HadleyElizabeth23HatcherJim2McHughTim24ThalasselisChris1TomlinsonMia1YongblahFrancis2, Julie Allen, Nadua Bayzid, Julianne Brown, Doug Burns, Elizabeth Hadley, Jim Hatcher, Tim McHugh, Chris Thalasselis, Mia Tomlinson, Francis Yongblah
[Category] update2024,
[Article Type] Article
[Source] PMC
In this clinical trial, the authors show that a 5-day molnupiravir treatment reduces SARS-CoV-2 viral load in at-risk outpatients by day 5 but mostly fails to clear virus, leads to lower spike antibody response by day 14 and higher virus mutation rates.
All Keywords
【저자키워드】 SARS-CoV-2, Randomized controlled trials, Drug development, Antiviral agents,